OSTP, in Partnership with ONC, Seeks Input on Optimizing Data Capture for Clinical Trials

The COVID-19 pandemic demonstrated the need for a coordinated clinical trials enterprise, one that can swiftly characterize emerging viral threats and evaluate the effectiveness of vaccines, therapeutics, and other countermeasures across a diversity of trial participants. In response, the Biden-Harris Administration released the National Biodefense Strategy, which calls for a U.S. clinical trials infrastructure “ready to administer candidate countermeasures to participants within 14 days after the identification of a viable countermeasure.” In support of this effort, the White House Office of Science & Technology Policy (OSTP), in coordination with the National Security Council, issued a Request for Information (RFI) on October 26 seeking input from the public about how a coordinated clinical research system can be deployed in the event of an emerging disease outbreak.

Read on healthit.gov